Trials / Completed
CompletedNCT01632137
Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
A Phase 3 Study to Determine the Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 564 (actual)
- Sponsor
- Kubota Vision Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of rebamipide ophthalmic suspension in subjects with dry eye syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rebamipide 2% ophthalmic suspension | Instill one drop into each eye 4 times a day for 4 weeks. |
| DRUG | Placebo (vehicle) | Instill one drop into each eye 4 times a day for 4 weeks. |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2013-06-01
- First posted
- 2012-07-02
- Last updated
- 2014-05-07
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01632137. Inclusion in this directory is not an endorsement.